NATURALS
5><8A<@"8A"5-6?8><@"9-"9;<"12H"84@" A
r><8A<@ A B A B B TQ UCP1
PRDM16 FGF21
ββ-actin
FGF21 -actin
eased as compared to the TQ- andω=H-4FG"E>-I?A"J$3EI><A"KL"84@"MNO" C
C C
1.0 0.8 0.6 0.4 0.2 0
1.0 0.8 0.6 0.4 0.2 0 C E E E C Sirt1 Sirt1
MfN2 HO-1
Mfn2 HO-1
β-actinβ-actin TQ TQ F FF
1.0 0.8 0.6 0.4 0.2 0
1.0 0.8 0.6 0.4 0.2 0 C C TQ ** TQ TQ G GG
1.0 0.8 0.6 0.4 0.2 0
1.0 0.8 0.6 0.4 0.2 0 C C TQ ** * * C
1.0 0.8 0.6 0.4 0.2 0
1.0 0.8 0.6 0.4 0.2 0 C TQ TQ H HH
1.0 0.8 0.6 0.4 0.2 0
1.0 0.8 0.6 0.4 0.2 0 C C TQ
Figure 3: Effects of BSO with 3% thymoquinone (TQ) treatment on the protein expression of beige adipocytes and key regulators of mitochondrial biogenesis in 3T3-L1 adipocytes. Representative and graph of uncoupling protein 1 (UCP-1), PR domain containing 16 (PRDM16), and fibroblast growth factor 21 (FGF21) (A–D); Sirtuin 1 (Sirt1) Mitofusion 2 (Mfn2), and heme oxygenase-1 (HO-1) protein expression (E–H). 3T3-L1 adipocytes were treated with TQ 2 μM, for six days (n=4)
superior fashion to that of a placebo cream. These results support the mechanisms related to the mitochondrial biogenesis and revitalization effects observed in vitro for BSO as well as its antioxidant and anti-inflammatory benefits. (Figure 7).
Conclusion Over the past 60 years, more than 1,000 clinical studies have been conducted to identify and support the many health and cosmetic benefits of Nigella sativa black seed oil. Standardized (3% thymoquinone and less than 2% free fatty acids), cold-pressed, non-GMO black seed oil has been studied in vitro to identify its mechanisms related to mitochondrial biogenesis and revitalization.
Undifferentiated Differentiated The ability of a topical active cream’s with
3% B’utyQuin to positively impact several characteristics of ageing human skin has been revealed. This clinical trial demonstrates that topical application of the active cream to a variety of healthy skin types over a 28-day period yields statistically significant improvements in skin hydration, elasticity, firmness and luminosity when compared to a placebo applied in the same fashion and for the same duration. The active cream was found to be superior in all dermatologist-measured aspects and resulted in a superior ‘flawless appearance’ of the skin compared to placebo. The B’utyQuin was also found to be very safe, causing no
0.16 0.14 0.12 0.10 0.08 0.06 0.04 0.02 0
TQ 3% 2uM TQ 3% 4uM TQ 3% 6uM * *# *# *#
adverse skin reactions over the course of the clinical trial. We conclude that the topical use of B’utyQuin
in cosmetic formulations is a safe, compatible, and effective tool for improving the characteristics of ageing skin in healthy subjects.
References 1. Salih B, Sipahi T, Dönmez EO. Ancient nigella seeds from Boyali Höyük in north-central Turkey. J. Ethnopharmacol. 2009;124(3):416- 420. doi:10.1016/
j.jep.2009.05.039
2. Manniche L. An Ancient Egyptian Herbal. London: British Museum Publications & Austin, TX. University of Texas Press. 1989
3. Ahmad A, Husain A, Mujeeb M et al. A review on therapeutic potential ofNigella sativa: A miracle herb. Asian Pac. J. Trop Biomed. 2013;3(5):337-352. doi: 10.1016/S2221- 1691(13)60075-1
4. Liang J, Lian L, Wang X, Li L. Thymoquinone, extract from Nigella sativa seeds, protects human skin keratinocytes against UVA- irradiated oxidative stress, inflammation and mitochondrial dysfunction. Mol. Immunol. 2021;135:21-27. doi:10.1016/
j.molimm.2021.03.015
Ctrl Und Ctrl Diff
BQ 3%
2uM
BQ 3%
4uM
BQ 3%
6uM
Figure 4: Effect of BSO with 3% thymoquinone oil on oil droplets formation in 3T3 adipocytes showed a significant reduction of lipid droplets formation in 3T3 adipocytes at day 6. (n=4), *#p<0.05 vs. control
www.personalcaremagazine.com
5. Chehl N, Chipitsyna G, Gong Q et al. Anti- inflammatory effects of the Nigella sativa seed extract, thymoquinone, in pancreatic cancer cells. HPB (Oxford) 2009;11(5):373–381. doi: 10.1111/j.1477-2574.2009.00059.x
6. El Mezayen R, El Gazzar M, Nicolls MR et al. Effect of thymoquinone on cyclooxygenase
October 2022 PERSONAL CARE PC ** ** D D D
1.0 0.8 0.6 0.4 0.2 0
1.0 0.8 0.6 0.4 0.2 0 C TQ TQ * *
91
SIRT1/β-actin (O.D.) SIRT1/β-actin (O.D.)
PRDM16/β-actin (O.D.)
PRDM16/ β-actin (O.D.)
Oil Red 0 (490nm) / Arbitrary Unit
MFN2/β-actin (O.D.) MFN2/β-actin (O.D.)
PRDM16/β-actin (O.D.)
PRDM16/ β-actin (O.D.)
MFN2/β-actin (O.D.) MFN2/β-actin (O.D.)
PRDM16/β-actin (O.D.)
PRDM16/ β-actin (O.D.)
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108
